StreetInsider.com News Articles

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

Mon, 19 Oct 2026 08:00:00 -0400

Presentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections

WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today it will present data from four abstracts at IDWeek 2026, the annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). The meeting will be held October 21–24, 2026, at the Walter E. Washington Convention Center in Washington, D.C.

The presentations cover two FDA-approved antibiotics marketed by Innoviva

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

Mon, 19 Oct 2026 08:00:00 -0400

Presentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections

The presentations cover two FDA-approved antibiotics marketed by Innoviva

Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform

Wed, 23 Sep 2026 06:55:23 -0400

(Updated - September 23, 2026 6:55 AM EDT)

Oppenheimer analyst Les Sulewski assumes coverage on Inova Technology, Inc. (NASDAQ: INVA) with a Outperform rating and a price target of $35.00.

The analyst comments "We assume coverage of Innoviva with an Outperform rating and $35 PT. We believe the market values INVA primarily as a declining respiratory royalty company while assigning limited credit to a fast-growing critical care and infectious disease platform and strategic healthcare assets. Durable Breo/Relvar and Anoro royalties fund IST growth, BD, strategic investments, and share repurchases. Xacduro and Giapreza lead current growth, while Zevtera, Nuzolvence, ex-US expansion, and potential

Oppenheimer Assumes Inova Technology, Inc. (INVA) at Outperform

Wed, 23 Sep 2026 06:55:23 -0400

(Updated - September 23, 2026 6:55 AM EDT)

Oppenheimer analyst Les Sulewski assumes coverage on Inova Technology, Inc. (NASDAQ: INVA) with a Outperform rating and a price target of $35.00.

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Zhen Marianne

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968278.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Zhen Marianne

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968278.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Basso Stephen

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968270.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Basso Stephen

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968270.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Raifeld Pavel

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968262.html

Form 4 Innoviva, Inc. For: Aug 20 Filed by: Raifeld Pavel

Mon, 24 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260824/26968262.html

Inova Technology (INVA) Reiterated at Overweight by Cantor Fitzgerald Post Webinar With CEO, CFO

Fri, 21 Aug 2026 08:35:20 -0400

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $34.00 price target on Inova Technology, Inc. (NASDAQ: INVA).

The analyst commented, "We hosted Innoviva for a broad update via webinar this week. The replay provides a great primer on Innoviva's history, as the company evolved from a royalty-only business into a diversified biopharma with a growing Innoviva Specialty Therapeutics (IST) commercial platform and a portfolio of strategic healthcare assets. INVA is profitably growing an underlying commercial business with a >50% CAGR historically, and the stock (~$1.5B market cap) is trading at < 8x TTM revenue (~$212M TTM) with respect to

Innoviva unit's three antibiotics named Prix Galien USA finalists

Tue, 11 Aug 2026 16:06:12 -0400

Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced that three of its infectious disease drugs — Xacduro, Zevtera, and Nuzolvence — have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category, according to a press release.

The company said this marks the third consecutive year one of its products has been recognized as a finalist by the Galien Foundation. The 2026 award winners are scheduled to be announced at a ceremony on October 29, 2026, in New York City.

Xacduro (sulbactam/durlobactam for injection) was approved by the FDA in May 2023 for

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Tue, 11 Aug 2026 16:05:00 -0400

WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics product has been recognized by the renowned Galien Foundation.